UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-06, Vol.17 (6), p.e0264741-e0264741

2022

Link zum Volltext

Verfügbarkeit prüfen

A not so easy genotype—striking regional differences in SOF / RBV treatment responses in HCV GT 2

Liver international, 2017-08, Vol.37 (8), p.1253-1254

2017

Link zum Volltext

Verfügbarkeit prüfen

Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV-Infektion

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2021, Vol.64 (5), p.625-634

2021

Link zum Volltext

Verfügbarkeit prüfen

Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs: Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward

Clinical infectious diseases, 2013, Vol.57

2013

Link zum Volltext

Verfügbarkeit prüfen

Therapy of HIV-HBV-coinfection

MMW Fortschritte der Medizin, 2009-04, Vol.151 (18), p.49

Mauss, Stefan

2009

Link zum Volltext

Verfügbarkeit prüfen

Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R)

Journal of hepatology, 2022-07, Vol.77, p.S562-S563

2022

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)

Journal of hepatology, 2022-07, Vol.77, p.S16

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply

Hepatology (Baltimore, Md.), 2014-09, Vol.60 (3), p.1110-1110

2014

Link zum Volltext

Verfügbarkeit prüfen

Reply

Hepatology (Baltimore, Md.), 2014-09, Vol.60 (3), p.1110

2014

Link zum Volltext

Verfügbarkeit prüfen

Reply

Hepatology (Baltimore, Md.), 2014-09, Vol.60 (3), p.1110-1110

2014

Link zum Volltext

Verfügbarkeit prüfen

Treatment of chronic hepatitis B

MMW Fortschritte der Medizin, 2008-04, Vol.150 Spec No 1, p.48

Mauss, Stefan

2008

Link zum Volltext

Verfügbarkeit prüfen

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir: Mauss, Hueppe, and Alshuth

Hepatology (Baltimore, Md.), 2014-01, Vol.59 (1), p.46-48

2014

Link zum Volltext

Verfügbarkeit prüfen

How do generic quotas work? An analysis using HIV infection as an example/Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV-Infektion

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2021-05, Vol.64 (5), p.625

2021

Link zum Volltext

Verfügbarkeit prüfen

Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)

Journal of hepatology, 2020-08, Vol.73, p.S348-S349

2020

Link zum Volltext

Verfügbarkeit prüfen

Inadvertent “off label” DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R)

Journal of hepatology, 2020-08, Vol.73, p.S335

2020

Link zum Volltext

Verfügbarkeit prüfen

THU401 - Inadvertent “off label” DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R)

Journal of hepatology, 2020-08, Vol.73, p.S335-S335

2020

Link zum Volltext

Verfügbarkeit prüfen

THU423 - Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)

Journal of hepatology, 2020-08, Vol.73, p.S348-S349

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure

Journal of hepatology, 2022-07, Vol.77, p.S585-S586

2022

Link zum Volltext

Verfügbarkeit prüfen

THU-161-Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R)

Journal of hepatology, 2019-04, Vol.70 (1), p.e232-e233

2019

Link zum Volltext

Verfügbarkeit prüfen

Groundbreaking new data for HIV and hepatitis B and C. What will change in 2010?

MMW Fortschritte der Medizin, 2010-04, Vol.152 (17), p.26-26

2010

Link zum Volltext

Verfügbarkeit prüfen

THU-176-Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R)

Journal of hepatology, 2019-04, Vol.70 (1), p.e239-e239

2019

Link zum Volltext

Verfügbarkeit prüfen

SAT286 - Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy?

Journal of hepatology, 2020-08, Vol.73, p.S795-S796

2020

Link zum Volltext

Verfügbarkeit prüfen

Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy?

Journal of hepatology, 2020-08, Vol.73, p.S795-S796

2020

Link zum Volltext

Verfügbarkeit prüfen

Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030/Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Journal of hepatology, 2017-08, Vol.67 (2), p.419

2017

Link zum Volltext

Verfügbarkeit prüfen

Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

The International journal of drug policy, 2023-01, Vol.111, p.101670-101670, Article 101670

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(51)
Deutsch
(7)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

A not so easy genotype—striking regional differences in SOF / RBV treatment responses in HCV GT 2

Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV-Infektion

Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs: Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward

Therapy of HIV-HBV-coinfection

Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R)

Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)

Reply

Reply

Reply

Treatment of chronic hepatitis B

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir: Mauss, Hueppe, and Alshuth

How do generic quotas work? An analysis using HIV infection as an example/Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV-Infektion

Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)

Inadvertent “off label” DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R)

THU401 - Inadvertent “off label” DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R)

THU423 - Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)

Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure

THU-161-Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R)

Groundbreaking new data for HIV and hepatitis B and C. What will change in 2010?

THU-176-Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R)

SAT286 - Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy?

Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy?

Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030/Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

Aktive Filter

Suchergebnisse filtern